DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
1 Year Est. Return
+99.04%
AUM
$8.48B
AUM Growth
+$676M
(+8.7%)
Holding
161
Top Buys
| 1 | +$83.8M | |
| 2 | +$82.1M | |
| 3 | +$80.9M | |
| 4 |
Genmab
GMAB
|
+$73.8M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$59.1M |
Top Sells
| 1 | +$76.2M | |
| 2 | +$60.3M | |
| 3 | +$33.8M | |
| 4 |
Ventas
VTR
|
+$27.4M |
| 5 |
Spyre Therapeutics
SYRE
|
+$23.3M |
Sector Composition
| 1 | Healthcare | 84.65% |
| 2 | Consumer Discretionary | 0% |
| 3 | Consumer Staples | 0% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$7.13B
| $1.77B | 20.85% |
17,248,450
|
|
||
2
Cogent Biosciences
COGT
$5.56B
| $348M | 4.11% |
9,043,903
|
|
||
3
Praxis Precision Medicines
PRAX
$8.22B
| $310M | 3.66% |
963,351
+60,000
|
|
||
4
Viatris
VTRS
$18.3B
| $273M | 3.22% |
20,206,170
|
|
||
5
United Therapeutics
UTHR
$22.9B
| $271M | 3.2% |
457,000
+31,007
|
|
||
6
Revolution Medicines
RVMD
$32.7B
| $223M | 2.64% |
2,297,000
-597,613
|
|
||
7
Celcuity
CELC
$4.67B
| $196M | 2.31% |
1,714,000
|
|
||
8
Centene
CNC
$30.2B
| $194M | 2.29% |
5,917,091
-530,907
|
|
||
9
Larimar Therapeutics
LRMR
$353M
| $160M | 1.89% |
35,606,974
+5,000,000
|
|
||
10
Brookdale Senior Living
BKD
$2.9B
| $159M | 1.88% |
11,637,032
|
|
||
11
Vera Therapeutics
VERA
$2.3B
| $150M | 1.77% |
3,722,100
-337,595
|
|
||
12
Ionis Pharmaceuticals
IONS
$12.1B
| $149M | 1.75% |
1,979,669
|
|
||
13
BioCryst Pharmaceuticals
BCRX
$2.11B
| $143M | 1.69% |
15,038,000
+697,000
|
|
||
14
Inspire Medical Systems
INSP
$1.15B
| $139M | 1.65% |
2,703,238
+1,197,366
|
|
||
15
Legend Biotech
LEGN
$6.03B
| $139M | 1.64% |
7,687,638
+1,755,638
|
|
||
16
AdaptHealth
AHCO
$1.34B
| $137M | 1.61% |
11,477,730
|
|
||
17
NewAmsterdam Pharma
NAMS
$3.67B
| $137M | 1.61% |
4,264,789
+100,000
|
|
||
18
Acadia Healthcare
ACHC
$2.28B
| $106M | 1.25% |
4,520,000
|
|
||
19
Arrowhead Research
ARWR
$9.98B
| $98.6M | 1.16% |
1,573,297
-259,649
|
|
||
20
Catalyst Pharmaceutical
CPRX
$3.83B
| $97.6M | 1.15% |
3,943,600
-967,561
|
|
||
21
Indivior Pharmaceuticals
INDV
$3.98B
| $94.4M | 1.11% |
3,097,790
-295,273
|
|
||
22
Xenon Pharmaceuticals
XENE
$5.16B
| $94M | 1.11% |
1,615,696
+1,073,676
|
|
||
23
Pharvaris
PHVS
$2.01B
| $88.3M | 1.04% |
3,126,042
|
|
||
24
Syndax Pharmaceuticals
SNDX
$1.66B
| $88.3M | 1.04% |
+3,779,900
|
|
||
25
Tango Therapeutics
TNGX
$3.18B
| $86.8M | 1.02% |
4,146,813
+1,239,867
|
|